Venture Capital and HealthTech: Insights and Strategies

July 28, 2024

The rise of health technology, or HealthTech, is revolutionizing the way healthcare is delivered and managed. HealthTech encompasses a wide array of innovations, from telemedicine and digital health records to wearable devices and AI-driven diagnostics. These technologies are enhancing patient care, improving health outcomes, and increasing the efficiency of healthcare systems worldwide.


Venture capital (VC) plays a crucial role in fostering innovation within the HealthTech sector. By providing essential funding, strategic guidance, and valuable networks, venture capitalists help HealthTech startups navigate the challenges of bringing new technologies to market. This support accelerates the development and adoption of cutting-edge solutions, driving the transformation of healthcare.


The purpose of this blog is to explore the dynamic landscape of HealthTech and the pivotal role of venture capital in this space. We will delve into insights and strategies for successful investments in HealthTech, providing valuable information for investors looking to capitalize on the growth and innovation within this sector.


The Growing HealthTech Market

Health technology, or HealthTech, refers to the application of technology to improve the delivery, efficiency, and quality of healthcare services. It encompasses a broad range of innovations, including telemedicine, digital therapeutics, wearable devices, electronic health records (EHRs), and artificial intelligence (AI) in healthcare. HealthTech aims to enhance patient care, streamline administrative processes, and facilitate better health outcomes through technological advancements.


The Role of Venture Capital in HealthTech

Venture capital (VC) plays a pivotal role in the development and success of HealthTech startups. These firms provide more than just financial support; they offer strategic guidance, mentorship, and valuable networking opportunities that can significantly accelerate a startup's growth and market entry.


1. Providing Capital for R&D and Scaling Operations Venture capital firms inject crucial funds that enable HealthTech startups to invest in research and development (R&D), refine their technologies, and scale their operations. This financial support is vital for startups to bring innovative health solutions to market and expand their reach. For example, the infusion of VC funding allows startups to hire top talent, invest in cutting-edge technology, and navigate the regulatory landscape more effectively.

2. Strategic Guidance and Mentorship Beyond capital, venture capitalists offer strategic advice and mentorship to HealthTech entrepreneurs. They help shape business strategies, refine value propositions, and develop go-to-market plans. Experienced VCs bring a wealth of knowledge from their involvement in multiple startups, providing insights that can help new companies avoid common pitfalls and accelerate their path to success.

3. Networking Opportunities and Partnerships Venture capital firms facilitate valuable connections within the industry, linking startups with potential partners, customers, and other stakeholders. These connections can lead to strategic partnerships, collaborations, and pilot projects that are essential for validating technologies and expanding market presence. The network effect of VC backing can also enhance a startup's credibility, making it easier to attract additional investors and customers.


Several prominent venture capital firms have made significant investments in the HealthTech sector, driving innovation and growth. These firms include:


  • Sequoia Capital: Known for its investments in companies like Apple, Google, and WhatsApp, Sequoia Capital has also backed HealthTech startups such as 23andMe and Guardant Health.
  • Andreessen Horowitz (a16z): A leading VC firm with a focus on technology and life sciences, a16z has invested in companies like Apeel Sciences, Devoted Health, and Honor.
  • Kleiner Perkins: With a strong portfolio in health and life sciences, Kleiner Perkins has supported companies like Livongo, Grail, and Oscar Health.


Challenges and Considerations for HealthTech Investors


HealthTech investors must navigate a complex regulatory landscape to ensure compliance with various healthcare regulations. Key regulations include:


  • FDA (Food and Drug Administration): The FDA oversees the approval of medical devices, software as a medical device (SaMD), and certain digital health tools. Compliance with FDA regulations is crucial for bringing HealthTech innovations to market in the United States.
  • HIPAA (Health Insurance Portability and Accountability Act): HIPAA sets national standards for the protection of patient health information. HealthTech companies must ensure that their technologies and data management practices comply with HIPAA requirements to safeguard patient privacy and data security.
  • GDPR (General Data Protection Regulation): In Europe, the GDPR provides a comprehensive framework for data protection and privacy. HealthTech companies operating in or serving the European market must adhere to GDPR guidelines to ensure the lawful processing of personal data.


Investors should prioritize startups with strong compliance strategies to mitigate regulatory risks. Key considerations include:


  • Regulatory Expertise: Assess whether the startup has in-house regulatory experts or consultants to navigate the regulatory environment effectively.
  • Compliance Programs: Evaluate the startup's compliance programs, including policies, procedures, and training programs, to ensure adherence to relevant regulations.
  • Audit Readiness: Determine if the startup is prepared for regulatory audits and inspections by reviewing their documentation and internal controls.


With the increasing digitization of healthcare, ensuring robust cybersecurity measures is paramount. HealthTech companies must protect sensitive patient data from breaches and cyberattacks. Key aspects of cybersecurity include:


  • Data Encryption: Implementing strong encryption protocols to protect data both in transit and at rest.
  • Access Controls: Establishing strict access controls to ensure that only authorized personnel can access sensitive information.
  • Security Audits: Regularly conducting security audits and assessments to identify vulnerabilities and implement corrective measures.


Investors should ensure that HealthTech startups prioritize data security by adopting the following strategies:


  • Data Anonymization: Using anonymization techniques to protect patient identities in datasets used for research and analysis.
  • Secure Cloud Storage: Utilizing secure cloud storage solutions that comply with industry standards and regulations for data protection.
  • Incident Response Plans: Developing and maintaining robust incident response plans to quickly address and mitigate the impact of data breaches.


The HealthTech market is dynamic and highly competitive. Investors must stay informed about market trends and competitor activities to make strategic investment decisions. Key strategies include:


  • Market Research: Conducting ongoing market research to understand emerging trends, technological advancements, and consumer preferences.
  • Competitive Analysis: Regularly analyzing competitors' strengths, weaknesses, opportunities, and threats (SWOT analysis) to identify potential risks and opportunities.


HealthTech is characterized by rapid technological advancements. Investors should ensure that startups are agile and adaptable to keep pace with technological changes. Key considerations include:


  • Innovation Culture: Evaluating whether the startup fosters a culture of innovation and continuous improvement.
  • R&D Investment: Assessing the startup's commitment to research and development (R&D) to stay at the forefront of technological advancements.
  • Strategic Partnerships: Encouraging startups to form strategic partnerships with tech companies, academic institutions, and research organizations to leverage external expertise and resources.


Investing in HealthTech offers significant opportunities for innovation and financial returns. However, it also comes with challenges that require careful navigation of regulatory and compliance issues, robust data privacy and security measures, and an ability to manage market volatility and competition. By addressing these challenges and adopting strategic investment practices, investors can contribute to the advancement of HealthTech solutions that transform healthcare delivery and improve patient outcomes.

Overview of Notable Labs and Its Mission

Notable Labs is a pioneering HealthTech company focused on personalizing cancer treatment through advanced drug testing and data analytics. The company’s mission is to transform the oncology treatment paradigm by rapidly identifying effective therapies tailored to individual patients' unique cancer profiles. By leveraging high-throughput screening and machine learning, Notable Labs aims to provide oncologists with actionable insights to improve patient outcomes.


Notable Labs has effectively utilized venture capital to fuel its innovation and growth. The influx of venture capital funding has enabled the company to invest in cutting-edge technologies, expand its research capabilities, and scale its operations. Key areas of investment include:


  • Research and Development (R&D): Capital has been directed towards developing and refining Notable's high-throughput drug screening platform, allowing for the rapid testing of thousands of drugs on patient-derived cancer cells.
  • Technology Integration: Investments in AI and machine learning have enhanced the company's ability to analyze complex data sets and identify promising drug combinations more efficiently.
  • Operational Expansion: Venture capital has facilitated the scaling of Notable’s laboratory facilities and the expansion of its team, including hiring top talent in oncology, bioinformatics, and data science.


Notable Labs has achieved several significant milestones that underscore its impact and potential in the HealthTech sector:


  • Breakthrough Drug Screening Platform: Development of a proprietary high-throughput drug screening platform that tests a wide array of drugs on patient-derived cancer cells, providing personalized treatment recommendations.
  • Clinical Partnerships: Establishment of partnerships with leading oncology centers and hospitals to integrate Notable’s technology into clinical practice, enhancing the personalization of cancer treatment.
  • Funding Rounds: Successful completion of multiple funding rounds, securing investments from prominent venture capital firms, which has further validated the company's business model and technological approach.
  • Regulatory Approvals: Attainment of necessary regulatory approvals for their drug screening tests, paving the way for broader clinical adoption and integration.


Lessons Learned from Notable Labs' Journey and Their Implications for Investors

Investors can glean valuable insights from Notable Labs' journey, particularly in the context of investing in HealthTech:


  • Innovation is Key: Investing in companies that prioritize innovation and leverage advanced technologies can lead to significant breakthroughs in healthcare.
  • Strategic Partnerships: Forming alliances with clinical and research institutions can enhance a startup’s credibility and facilitate market entry.
  • Regulatory Navigation: Ensuring robust strategies for navigating the regulatory landscape is crucial for the successful commercialization of HealthTech solutions.
  • Scalability: Investors should look for scalable business models that can adapt to growing demand and technological advancements.


Future Directions in HealthTech and Venture Capital


Emerging Trends and Technologies in HealthTech

The HealthTech landscape is continuously evolving, with several emerging trends and technologies poised to shape the future:

  • AI and Machine Learning: AI and machine learning are becoming increasingly integral in HealthTech, offering capabilities such as predictive analytics, personalized treatment plans, and improved diagnostic accuracy.
  • Blockchain for Health Data Security: Blockchain technology is emerging as a robust solution for securing health data, ensuring data integrity, and facilitating secure data exchange among healthcare providers.
  • Personalized Medicine: Advances in genomics and biotechnology are driving the growth of personalized medicine, enabling treatments tailored to individual genetic profiles and specific disease characteristics.


Expected Market Developments:

  • Continued Growth: The HealthTech market is expected to grow significantly, driven by technological advancements, increasing healthcare demand, and ongoing innovation.
  • Increased Adoption of Digital Health Solutions: Telemedicine, remote patient monitoring, and mobile health applications will see broader adoption as healthcare providers and patients recognize their benefits.
  • Greater Focus on Data Security: As the volume of health data grows, ensuring its security will become a top priority, with investments in cybersecurity solutions expected to rise.


Potential Areas of Growth and Innovation:

  • Wearable Devices: The market for wearable health devices is set to expand, offering continuous health monitoring and real-time data collection.
  • Genomic Medicine: Innovations in genomic medicine will drive the development of new diagnostic tools and targeted therapies, making personalized healthcare more accessible.
  • Health Data Analytics: Advanced data analytics will play a crucial role in managing health data, providing insights for improving patient care, and optimizing healthcare operations.


The convergence of HealthTech and venture capital presents a dynamic landscape filled with opportunities and challenges. By understanding the key trends, leveraging strategic investments, and navigating the regulatory environment, investors can play a pivotal role in shaping the future of healthcare. Companies like Notable Labs exemplify how innovation and venture capital can come together to drive significant advancements, offering valuable lessons and insights for aspiring HealthTech investors.


Future Directions in HealthTech and Venture Capital


Artificial intelligence (AI) and machine learning (ML) are transforming HealthTech by enhancing diagnostic accuracy, predicting patient outcomes, and personalizing treatment plans. These technologies analyze vast datasets to uncover patterns and insights that might be missed by human analysis. For instance, AI-powered tools can detect early signs of diseases like cancer from medical imaging with higher accuracy than traditional methods.


  • Predictive Analytics: AI and ML algorithms can predict patient outcomes and disease progression by analyzing historical data. This enables proactive interventions and personalized treatment plans.
  • AI in Diagnostics: AI-driven diagnostic tools are helping radiologists and pathologists detect diseases with greater precision. For example, Google's DeepMind has developed an AI system that can diagnose eye diseases from retinal scans with high accuracy.
  • Treatment Personalization: AI systems analyze patient data, including genetic information, to recommend personalized treatment plans, ensuring better outcomes and fewer side effects.


Blockchain technology offers a secure way to manage and share health data. By providing a decentralized and immutable ledger, blockchain ensures data integrity and enhances privacy.


  • Data Security: Blockchain's encryption capabilities make it difficult for unauthorized users to access sensitive health information, thereby protecting patient privacy.
  • Interoperability: Blockchain facilitates seamless data exchange across different healthcare systems, ensuring that patient information is accessible to authorized parties while maintaining security.
  • Transparent and Immutable Records: Blockchain creates a transparent and tamper-proof record of all transactions, enhancing trust in health data management and reducing fraud.


Personalized medicine tailors healthcare to individual genetic profiles, offering more effective treatments with fewer side effects. Advances in genomics and biotechnology are driving the growth of personalized medicine, making it a key area of innovation in HealthTech.


  • Genomic Sequencing: The decreasing cost of genomic sequencing allows for more widespread use of personalized medicine, helping to identify the most effective treatments for individual patients based on their genetic makeup.
  • Targeted Therapies: Personalized medicine enables the development of targeted therapies that are designed to work best for specific genetic profiles, improving treatment outcomes and reducing adverse reactions.
  • Preventive Healthcare: By understanding an individual's genetic risk factors, personalized medicine can facilitate early interventions and preventive measures, potentially avoiding the onset of serious diseases.


The HealthTech market is poised for substantial growth, driven by technological advancements, increasing healthcare demand, and the ongoing impact of the COVID-19 pandemic.


  • Market Size and Growth: The global HealthTech market is projected to grow significantly, with estimates suggesting it could reach over $500 billion by 2027. Key drivers include the rising prevalence of chronic diseases, the need for efficient healthcare delivery, and advancements in technology.
  • Adoption of Telemedicine: The use of telemedicine is expected to continue its upward trajectory, driven by patient demand for convenient, remote healthcare options and ongoing innovations in telehealth platforms.
  • Expansion of Digital Therapeutics: Digital therapeutics, which use software-based interventions to prevent, manage, or treat medical conditions, are gaining traction and are expected to become a major segment within the HealthTech market.
  • Wearable Health Devices: The market for wearable health devices, such as fitness trackers and smartwatches, is expanding as consumers seek to monitor their health in real-time. These devices provide valuable health data that can be integrated into broader healthcare management systems.
  • Health Data Analytics: Advanced data analytics will play a critical role in managing and interpreting the vast amounts of data generated by HealthTech devices and systems. Analytics can provide actionable insights for improving patient care and operational efficiency.
  • Virtual and Augmented Reality (VR/AR): VR and AR technologies are finding applications in medical training, patient care, and therapy. These technologies offer immersive experiences that can enhance learning and improve patient outcomes.
  • Blockchain Technology: Blockchain’s potential for securing health data and facilitating interoperability will drive its adoption in the healthcare sector. As data security concerns grow, blockchain offers a robust solution for managing and sharing sensitive health information.
  • Artificial Intelligence (AI): AI’s capabilities in predictive analytics, diagnostics, and personalized treatment plans will continue to expand, driving further innovation and improving healthcare outcomes.


By keeping abreast of these trends and understanding the factors driving growth in HealthTech, investors can identify high-potential opportunities and make informed decisions that align with the future direction of the healthcare industry. As technologies evolve and healthcare demands increase, the intersection of HealthTech and venture capital will remain a dynamic and promising field for innovation and investment.


Conclusion


Venture capital plays a pivotal role in the growth and evolution of the HealthTech sector. By providing essential funding, strategic guidance, and networking opportunities, venture capitalists help HealthTech startups innovate and scale their operations. This support is crucial for the development of new technologies that can transform healthcare delivery, improve patient outcomes, and reduce costs. The infusion of venture capital into HealthTech not only accelerates technological advancements but also drives the commercialization of groundbreaking solutions that address critical healthcare challenges.

Throughout this blog, we have explored various aspects of investing in HealthTech, from understanding the market landscape to identifying high-potential startups. Here are the key takeaways:


  1. Growing HealthTech Market: The HealthTech market is expanding rapidly, driven by technological advancements, increased healthcare demand, and the impact of the COVID-19 pandemic. Key sectors include telemedicine, digital therapeutics, and wearable devices.
  2. Role of Venture Capital: Venture capital is instrumental in fostering innovation in HealthTech by providing financial resources, strategic mentorship, and valuable industry connections. Notable venture capital firms and successful HealthTech companies exemplify the impact of venture capital investments.
  3. Investment Insights: Evaluating HealthTech startups requires a focus on innovation, market need, leadership quality, regulatory compliance, and scalability potential. Understanding the target market and competitive landscape is essential for making informed investment decisions.
  4. Strategies for Success: Successful investment strategies include diversifying portfolios within HealthTech, conducting thorough due diligence, managing risks, and building strategic partnerships. Collaborating with healthcare providers, tech companies, and regulatory bodies enhances growth opportunities.
  5. Challenges and Considerations: Navigating regulatory and compliance issues, addressing data privacy and security concerns, and managing market volatility are critical challenges. Staying informed about market trends and technological changes is crucial for maintaining a competitive edge.
  6. Spotlight on Notable Labs: Notable Labs exemplifies successful HealthTech innovation, leveraging venture capital to drive advancements in precision medicine. Their journey offers valuable lessons for investors and highlights the potential of combining digital health and personalized medicine.


As the HealthTech sector continues to grow and evolve, the opportunities for impactful investments are immense. Investors are encouraged to explore and support innovative HealthTech startups that are at the forefront of technological advancements. By strategically investing in these companies, investors can contribute to the transformation of healthcare, driving improvements in patient care, operational efficiency, and overall health outcomes.


Now is the time to capitalize on the momentum in HealthTech. Whether you are a seasoned investor or new to the sector, focusing on emerging technologies and trends can yield significant returns while making a meaningful impact on global healthcare. Support the startups that are shaping the future of health technology and be part of a movement that is revolutionizing how healthcare is delivered.


By prioritizing ethical practices, data security, and inclusive research, investors can ensure that their contributions lead to sustainable and equitable advancements in HealthTech. Embrace the future of healthcare by investing in the innovations that are redefining the industry and improving lives worldwide.

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts